

Asian Research Journal of Mathematics

Volume 20, Issue 8, Page 76-91, 2024; Article no.ARJOM.120065 ISSN: 2456-477X

A Mathematical Model for Rotavirus Infection Incorporating Time Delay on the Effectiveness of Vaccination with Treatment

Wakwabubi N. Christine ^{a*}, Samuel B. Apima ^b and Bonface Kwach ^a

^aDepartment of Mathematics, Kibabii University, Kenya. ^bDepartment of Mathematics and Statistics, Kaimosi Friends University, Kenya.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: https://doi.org/10.9734/arjom/2024/v20i8818

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/120065

Original Research Article

Received: 05/05/2024 Accepted: 11/07/2024 Published: 30/07/2024

Abstract

Rotavirus is the most common cause of severe diarrheal disease in young children globally attributing approximately 527,000 deaths of children under five each year. A Rotavirus vaccine was developed in 1998, however, it takes time for vaccine induced immunity to take place. The aim of the study was develop and analyze a mathematical model on rotavirus infection which incorporated a time delay on effectiveness of vaccination with treatment. The developed model was shown to be positively invariant and bounded.Conditions for stability of the equilibrium points is obtained and it is also shown that a bigger time

*Corresponding author: E-mail:wakwabubichristine@gmail.com;

Cite as: Christine, Wakwabubi N., Samuel B. Apima, and Bonface Kwach. 2024. "A Mathematical Model for Rotavirus Infection Incorporating Time Delay on the Effectiveness of Vaccination With Treatment". Asian Research Journal of Mathematics 20 (8):76-91. https://doi.org/10.9734/arjom/2024/v20i8818.

delay would make the population not to be predictable. The findings of this study is useful to the government, ministry of Health stakeholders and policy developers and further provides baseline information for studies of this nature.

Keywords: Delay; disease free equilibrium; endemic equilibrium point; rotavirus; stability analysis.

2010 Mathematics Subject Classification: 53C25; 83C05; 57N16.

1 Introduction

Diarrheal disease is the second leading cause of under-five mortality worldwide [1]. Rotavirus is the most common cause of severe diarrheal disease in young children globally, attributing to more than 25 million clinic visits, an estimated 2 million hospitalizations, and approximately 527,000 deaths of children under 5 each year [2]. However, the great proportion of the burden of rotavirus is borne by young children in developing countries.

Rotaviruses were discovered in the 1960s in animals. It was first discovered in humans by electron microscopy in duodenal biopsies from children with acute gastroenteritis [3]. It gets its name from the fact that under microscope, the virus resembles a wheel [4, 5]. Rotaviruses are 70-nm icosahedral viruses that belong to the family Reoviridae [6]. There are seven serogroups of rotavirus namely A, B, C, D, E, F and G. Most human pathogens belong to groups A, B, and C. Group A rotaviruses are most commonly found in humans and hence important from a public health standpoint. The virus is composed of three protein shells, an outer capsid, an inner capsid, and an internal core, that surround the 11 segments of double-stranded RNA. Four major structural and nonstructural proteins are of interest in vaccine development: VP6, NSP4, VP7, and VP4. VP6, the most abundant viral structural protein, is found in the inner capsid [7].

Rotavirus spreads by contact with infected faeces and might also be transmitted through faecal-contaminated: food, objects or surfaces, water, hands and respiratory droplets. The incubation period is about two days [8, 9, 5]. Once ingested, the virus that is not neutralized by stomach acid attaches to the proximal small intestine. During the incubation period of 18-36 hours, the virus enters epithelial cells where it first elaborates a potent enterotoxin NSP4 that can cause diarrhoea, and then goes on after 18–36 hours to destroy the epithelial surface leading to blunted villi, extensive damage, and shedding of massive quantities of virus (more than 10^{12} particles per gram) in stools [5]. The outcome is a profuse watery diarrhea with loss of fluid and electrolytes that can last 2–7 days and might lead to severe or fatal dehydration. The diagnosis of rotavirus infection is commonly done clinically, although a rapid antigen stool test is available. Children between 6 to 24 months of age can be infected with rotavirus several times during their lives, and infection can occur despite very high standards of hygiene [4]. Few clinical or epidemiological features distinguish a child with rotavirus from a child with diarrhea of any other cause. Newborn babies can be infected in the nursery, but these infections are often asymptomatic, perhaps because of the protective effect of circulating maternal antibodies of 27–30. However, first infections in children 3-24 months of age most often lead to vomiting, then watery diarrhoea that is sometimes accompanied by fever. In temperate climates, rotavirus has a distinct peak in the cooler winter months when it is the predominant pathogen causing up to 70 percent of hospital admissions for diarrhea [10].

After a single natural infection, 38 percent of children are protected against any subsequent rotavirus infection, 77 percent are protected against rotavirus diarrhoea and 87 percent are protected against severe diarrhoea. Malnutrition or co-infection with multiple enteric pathogens, common in developing countries, can further hinder effective rotavirus treatment, delay recovery, and lead to further sequelae, such as growth and developmental delays and susceptibility to re-infection which can occur at any age. Therefore, prevention of rotavirus through immunization is considered a global priority to manage the disease. However, with each infection immunity develops and this makes subsequent infections less severe [9, 1, 4].

Vaccination is the administration of antigenic material (vaccine) into the body to stimulate an individual's immune system to develop adaptive immunity to a pathogen [11, 12]. To date, vaccination is considered

the most effective and cost-beneficial intervention for protection against infectious diseases. The introduction of variolation in the 17th century and the intense vaccination programs that followed led to the worldwide eradication of smallpox by 1980. Further vaccinations that followed lead to more than 90 percent reduction of polio outbreaks as well as a significant reduction of pertussis, diphtheria, varicella, measles, and tetanus cases, saving millions of lives from preventable diseases, such as influenza, worldwide [13]. Immunizations have led to drastic improvements not only in developing and emerging countries but also in developed countries [13, 14, 15].

Rotavirus vaccine is a vaccine used to protect against rotavirus infections. The vaccine contains a weakened strain of rotavirus. This helps the body to build up immunity to fight off the disease in the event of an infection [16, 17, 18, 19, 20]. There are two types of rotavirus vaccines namely Rota teq (pentavalent human bovine reassortant) and Rotarix (Glaxosmithkline human monvalent) currently licensed for use. In addition, several developing country manufacturers are developing a new pipeline of rotavirus vaccines [6]. Introduction of rotavirus vaccine should be accompanied by measures to ensure high vaccination coverage and timely administration of each dose [21, 22, 23, 24].

In 2007, the World Health Organization (WHO) [2] recommended routine vaccination against rotavirus worldwide. Due to concern for infolding of one segment of the intestine within the other, a rare adverse event associated with an early-generation rotavirus vaccine no longer in use, WHO initially recommended that the first and last doses of RV5 and RV1 be given by 15 and 32 weeks of age, respectively. In January 2013, after re-evaluating the potential benefits and risks of rotavirus vaccination, WHO recommended removing these age restrictions [24]. However, it is anticipated that implementation of this recommendation has been challenging in both already existing and subsequent rotavirus vaccination programs as countries would need to adopt this recommendation, update their national immunization program guidelines, and retrain vaccinators [25].

A study on delayed vaccination and its predictors among children under 2 years in India has been done. The study reported that the vaccine timeliness is an under-recognised problem in India despite high proportion of Indian children having delayed vaccination. The targeted groups with higher chances of delayed vaccination included children delivered at home, low birth weight new-borns, poorer households, children of mothers with lower education, children from Muslim families which are integral when designing routine immunization microplan in the primary care settings [26]. A study of the timeliness of rotavirus vaccination at sentinel sites in four early-adopter African countries has been done. The study focused on age-eligible children to have received rotavirus vaccine that were enrolled in Ghana, Zimbabwe, Rwanda and Burkina Fasso using logistic regression technique. It was noted that delayed administration of first dose pentavalent vaccine was significantly associated with missing first dose of rotavirus vaccine in 3 of the 4 countries studied, although delays in administration were rare (1–4) percent and that age restrictions had minimal impact on rotavirus vaccine use due to timely vaccine administration [25, 26].

Investigations of delayed pertussis vaccination in infants using mathematical modeling, a methodology that involves the use of data collected from vaccination centres and an age-structured deterministic mathematical model for pertussis transmission was developed. The results obtained showed that strategies that avoid delays in vaccination have a strong impact on incidence reduction in the most vulnerable population (infants less than 1 year). In regions with high vaccination coverage (95) percent the elimination of delays in the three primary doses decreased pertussis incidence in infants by approximately 20 percent. In regions where delays in the administration of vaccines was higher, the combined action to reduce delays and improve coverage lead to a significant improvement in disease control in infants [27, 28, 29, 30].

In order to mitigate the diarrhoeal hazards of rotavirus, it is therefore necessary to employ both the prevention and precaution measures and the treatment methods available. The proposed study hence seeks to use a mathematical model to uncover and predict the dynamics of rotavirus infection by considering both vaccination and treatment parameters.

2 Model Description and Analysis

The assumptions in the model development were;

i Recruitment into the population is by birth or migration.

- ii The population under study is homogeneous.
- iii The mass action incidence transmission is defined by βSI

The model subdivided the total population at a time t given as N(t) into five compartments. The first compartment has the individuals that are susceptible to Rotavirus infections, it is denoted by S(t). The second compartment has the individuals infected with Rotavirus infection, it is denoted by I(t). The number of Individuals seeking treatment from Rotavirus infection and the individuals who have recovered from Rotavirus infection are denoted by T(t) and R(t), respectively. The individuals vaccinated from Rotavirus infection are represented by V(t).

The total population is; N(t)=S(t)+I(t)+T(t)+R(t)+V(t).

The parameters used in the formulated model include $(1-\rho)\wedge$ which denotes the recruitment rate into susceptible compartment. Recruitment rate into vaccination is denoted by $\rho\wedge$ while the rate at which vaccinated individuals become susceptible to Rotavirus is denoted by γ . Vaccination rate of the susceptible class is denoted by ω while ε denotes the expected decrease in the risk of infection. Rate of flow from I to T is denoted by k while β denotes transmission rate. Natural death rate of human is denoted by μ while δ denotes rotavirus induced deaths on compartment I. Time delay in completion of vaccination immunity is denoted by τ while a denotes Rotavirus induced death on compartment T. Recruitment rate from R to S is denoted by b while c denotes recruitment rate from T to R.

The proposed model is represented by the following system of equations.

$$\frac{dS}{dt} = (1-\rho) \wedge +\gamma V + bR - (\omega + \beta I + \mu)S$$

$$\frac{dV}{dt} = \rho \wedge +\omega S - \vee (\mu + \gamma) - ((1-\varepsilon)\beta \vee (t-\tau)I)$$

$$\frac{dI}{dt} = \beta SI - (\mu + \delta + k - (1-\varepsilon)\beta \vee (t-\tau))I$$

$$\frac{dT}{dt} = kI - (\mu + a + c)T$$

$$\frac{dR}{dt} = cT - (\mu + b)R$$

$$S(0) \geq 0, I(0) \geq 0, T(0) \geq 0, R(0) \geq 0, V(0) \geq 0$$
(2.1)

2.1 Invariant region

The invariant region gives the region of study. The model in equation 2.1 is analysed in a feasible bounded region Π that was defined as: $\Pi = \left\{ (S(t), V(t), I(t), T(t), R(t) \in \Re^5_+ : N(t) \leq \frac{\Lambda}{\mu} \right\}$

To show that the region Π is a bounded set, the time derivative of N was taken as follows;

$$\frac{dN}{dt} = \frac{dS}{dt} + \frac{dV}{dt} + \frac{dI}{dt} + \frac{dT}{dt} + \frac{dR}{dt}$$
(2.2)

Substituting the right-hand of equation 2.2 with its equivalence from equation 2.1 and simplifying we have:

$$\frac{dN}{dt} = \wedge -\mu(S + V + I + T + R) - \delta I - aT$$

$$\frac{dN}{dt} = \wedge -\mu N - (\delta I + aT)$$
(2.3)

For any increasing population $(\delta I + aT) > 0$ holds. Thus, if rotavirus induced deaths were not considered then;

$$\frac{dN}{dt} \le \wedge -\mu N$$
$$\frac{dN}{dt} + \mu N \le \wedge$$
(2.4)

Solving equation 2.4 by separation of variables we get;

$$N(t) \le \frac{\Lambda}{\mu} + N(0)e^{-\mu(t)}$$
 (2.5)

From inequality in equation 2.5, and since $N(t) \ge 0$, then

$$0 \le N(t) \le \frac{\Lambda}{\mu} + N(0)e^{-\mu(t)}$$
 (2.6)

where N(0) is initial population. Thus as $t \to \infty$, we have;

$$0 \le N(t) \le \frac{\wedge}{\mu}.$$
(2.7)

This implies that the total population is bounded. Therefore the model is well posed and biologically meaningful

2.2 Positivity of solutions

The model dealt with rotavirus infection in a varying human population size. Therefore the associated state variables were to be shown that they were non-negative for all time $t \ge 0$.

Theorem 2.1. Given the model in equation 2.1 with conditions $V(0) \ge 0, I(0) \ge 0, T(0) \ge 0, S(0) \ge 0, R(0) \ge 0$ then the solutions set S(t), V(t), I(t), T(t), R(t) of the model remain positive for all time $t \ge 0$ in the feasible region Π

Proof. Given the initial conditions $V(0) \ge 0, I(0) \ge 0, T(0) \ge 0, S(0) \ge 0, R(0) \ge 0$ for $t \ge 0$ it is shown that the solutions of equation 2.1 will remain to be positive. This is done by showing that each of the trajectories of the system in equation 2.1 was non-negative for all $t \ge 0$. Considering the first equation of 2.1, we had:

$$\frac{dS}{dt} = (1-\rho) \wedge +\gamma V + bR - (\omega + \beta I + \mu)S$$
(2.8)

The resulting differential inequality was given as;

$$\frac{dS}{dt} \ge -(\omega + \beta I + \mu)S \tag{2.9}$$

Using separation of variables method, you get;

$$\int \frac{dS}{S} \geq -\int (\omega s + \beta I + \mu) dt$$

$$S(t) \geq S_0 e^{-(\omega + \beta I + \mu)(t)}$$
(2.10)

which is positive. Repeating the same process of integration for V(t), I(t), T(t), R(t) in equation 2.1 we get;

$$V(t) \geq V_0 e^{-(\mu+\gamma)-(1-\varepsilon)\beta(t-\tau)(t)}$$

$$I(t) \geq I_0 e^{-(\mu+\delta+k)(t)}$$

$$T(t) \geq T_0 e^{-(\mu+a+c)(t)}$$

$$R(t) \geq R_0 e^{-(\mu+b)(t)}$$
(2.11)

respectively.

Hence all the solutions of the model in equation 2.1 remained positive in the feasible bounded region Π

2.3 Disease-free equilibrium point (DFE)

It is denoted by E^0 . Olaniyi and Obabiyi [31] defined it as a steady-state solution for which there is no disease or infection in the population. To obtain disease-free equilibrium point, we set the system in equation 2.1 equal to zero and solve for S(t), V(t), I(t), T(t), R(t). We set I(t) = T(t) = R(t) = 0 since there were no infections and obtained E^0 of model 2.1 as

$$E^{0} = [S^{0}, V^{0}, 0, 0, 0]$$

$$(1 - a) + \alpha V^{0} - \mu S^{0} - \alpha S^{0} = 0$$

$$(2.12)$$

$$(1 - \rho) + \gamma V^{0} - \mu S^{0} - \omega S^{0} = 0$$

$$\rho \wedge + \omega S^{0} - \mu V^{0} - \gamma V^{0} = 0$$
(2.13)

Solving for S^0 and V^0 from the system in equation 2.13, we get;

$$S^{0} = \frac{(1-\rho)\wedge +\gamma V^{0}}{\mu+\omega}$$
(2.14)

$$V^0 = \frac{\rho \wedge +\omega S^0}{\mu + \gamma} \tag{2.15}$$

Substituting equation 2.15 into equation 2.14 and solving for S^0 , we get;

$$S^{0} = \frac{(1-\rho) \wedge (\mu+\gamma) + \gamma \rho \wedge}{(\mu+\omega)(\mu+\gamma) - \gamma \omega}$$
(2.16)

Substituting equation 2.16 into to equation 2.15 and solving for V^0 , we get;

$$V^{0} = \frac{\rho \wedge + \omega(1-\rho) \wedge (\mu+\gamma) + \gamma \rho \wedge}{(\mu+\gamma)(\mu+\omega)(\mu+\gamma) - \gamma \omega}$$
(2.17)

81

2.3.1 The basic reproduction number R_0

The next generation matrix approach was used to determine the basic reproduction number denoted by R_0 . According to [31], it is defined as the number of secondary infections produced by a single typical infection introduced into a completely susceptible population. R_0 is used to measure the ability of an infection reproducing itself. The basic reproduction number was obtained as;

$$R_0 = Spectral \ radius \ of \ the \ matrix \ FV^{-1} \tag{2.18}$$

which are the dominant eigenvalues of FV^{-1} . F and V are computed and given as in the following 5×5 matrices by first determining f and v.

A new infection term, f, was defined as;

$$f = (F_1, F_2, F_3, F_4, F_5)^T$$

and was given by;

$$f = (0, 0, \beta SI + (1 - \varepsilon)\beta V(t - \tau)I, 0, 0)^{T}$$

V(transition term) was given as;

$$v = (0, 0, kI + \mu I + \delta I, 0, 0)^T$$

To obtain F and V, the partial derivatives of f and v were evaluated at the disease free equilibrium point. F and V were given as follows;

$$F = \beta S + (1 - \varepsilon)\beta V(t - \tau) V = k + \mu + \delta$$

On computing the inverse of V, V^{-1} we have;

$$V^{-1} = \frac{1}{k + \mu + \delta}$$
(2.19)

$$FV^{-1} = \frac{\beta}{k+\mu+\delta}S + (1-\varepsilon)V(t-\tau)$$
(2.20)

substituting S_0 and V_0 at DFE, we get;

$$R_0 = \frac{\beta}{k+\mu+\delta}S_0 + (1-\varepsilon)V_0(t-\tau)$$
(2.21)

In the absence of the disease then the delay $\tau = 0$, thus;

$$R_0 = \frac{\beta}{k + \mu + \delta} S_0 + (1 - \varepsilon) V_0(t)$$
(2.22)

2.3.2 Local stability of the disease free equilibrium point

Theorem 2.2. The DFE is asymptotically stable if:

$$\beta[S^0 + (1 - \varepsilon)] < \gamma + \delta + k \tag{2.23}$$

Proof. The Jacobian matrix of the models in Mathematics is used to evaluate the local stability of the system at E^0 using the signs of determined corresponding eigenvalues. The Jacobian matrix of equation 2.1 was given by;

$$J = \begin{pmatrix} -(A_1 + \beta I) & \gamma & \beta S & 0 & b \\ \omega & -A_2 - A_3 \frac{dV(t-\tau)}{dV(t)} \beta I & A_3 V(t-\tau) \beta I & 0 & 0 \\ \beta I & A_3 \frac{dV(t-\tau)}{dV(t)} \beta I & \beta S + A_3 V(t-\tau) \beta - A_4 & 0 & 0 \\ 0 & 0 & k & -A_5 & 0 \\ 0 & 0 & 0 & c & -A_6 \end{pmatrix}$$
(2.24)

Where $A_1 = \omega + \mu$, $A_2 = \gamma + \mu$, $A_3 = 1 - \varepsilon$, $A_4 = \mu + \delta + k$, $A_5 = \mu + a + c$ and $A_6 = \mu + b$

At E^0 , the Jacobian matrix above becomes;

$$J_{1} = \begin{pmatrix} -A_{1} & \gamma & \beta S^{0} & 0 & b\\ \omega & -A_{2} & 0 & 0 & 0\\ 0 & 0 & \beta S^{0} + \beta A_{3} V - A_{4} & 0 & 0\\ 0 & 0 & k & -A_{5} & 0\\ 0 & 0 & 0 & c & -A_{6} \end{pmatrix}$$
(2.25)

Whose eigenvalues are found to be: $\lambda_1 = -A_6, \lambda_2 = -A_5, \lambda_3 = -A_2, \lambda_4 = -A_1$ and $\lambda_5 = \beta S^0 + \beta A_3 V - A_4$ which are negative if:

$$\beta S^0 + \beta A_3 < A_4 \tag{2.26}$$

Therefore the eigenvalues are negative if the condition in the inequality in equation 2.26 holds, implying that the disease free equilibrium system is asymptotically stable as long as $R_0 < 1$.

2.4 Endemic equilibrium point

It is denoted by E^* . Olaniyi and Obabiyi [31] defined it as a steady-state solution for which there exists a constant occurrence of disease within the population. It occurs when the disease persists in the community. To obtain the endemic equilibrium point, the system in equation 2.1 was equated to zero and solved for (S(t), V(t), I(t), T(t), R(t)) which were denoted by;

$$E^* = S^*(t), V^*(t), I^*(t), T^*(t), R(t)$$
(2.27)

The points are generated;

$$S^{*} = \frac{k + \mu + \delta - (1 - \varepsilon)\beta V^{*}(t - \tau)}{\beta}$$

$$V^{*} = \frac{\beta S^{*}I^{*} + \mu S^{*} - bR^{*} - (1 - \rho)\wedge}{\gamma}$$

$$I^{*} = \frac{\rho}{\wedge} + \omega S^{*} - \mu V^{*} - \gamma V^{*}(1 - \varepsilon)\beta V^{*}(t - \tau)$$

$$T^{*} = \frac{kI^{*}}{\mu + a + c}$$

$$R^{*} = \frac{cT^{*}}{\mu + b}$$
(2.28)

83

2.4.1 Local stability of the endemic equilibrium point

The Jacobian matrix of equation 2.1 at endemic state $E^* = S^*, V^*, I^*, T^*, R^*$ was given by:

$$J_{2} = \begin{pmatrix} -(A_{1} + \beta I^{*}) & \gamma & \beta S^{*} & 0 & b \\ \omega & -A_{2} - A_{3}e^{-\lambda\tau}\beta I^{*} & -A_{3}V^{*}(t-\tau)\beta & 0 & 0 \\ \beta I^{*} & A_{3}e^{-\lambda\tau}\beta I^{*} & \beta S^{*} + A_{3}V^{*}(t-\tau)\beta - A_{4} & 0 & 0 \\ 0 & 0 & k & -A_{5} & 0 \\ 0 & 0 & 0 & c & -A_{6} \end{pmatrix}$$
(2.29)

Therefore

$$J_{2} = \begin{pmatrix} -G_{1} & \gamma & G_{2} & 0 & b \\ \omega & -G_{3} & -G_{4} & 0 & 0 \\ G_{5} & G_{6} & G_{7} & 0 & 0 \\ 0 & 0 & k & -A_{5} & 0 \\ 0 & 0 & 0 & c & -A_{6} \end{pmatrix}$$
(2.30)

Where $G_1 = (A_1 + \beta I^*), G_2 = \beta S^*, G_3 = A_2 + A_3 e^{-\lambda \tau} \beta I^*, G_4 = A_3 V^* (t - \tau) \beta G_5 = \beta I^*, G_6 = A_3 e^{-\lambda \tau} \beta I^*, G_7 = \beta S^* + A_3 V^* (t - \tau) \beta - A_4$

From matrix J_2 goven in equation 2.30, the trace:

 $traJ_2 = -G_1 - G_3 + G_7 - A_5 - A_6$ Which is negative if

$$G_7 < G_1 + G_3 + A_5 + A_6 \tag{2.31}$$

The determinant for equation 2.30 is given by: $det J_2 = bckG_3G_5 + A_5A_6G_2G_3G_5 - \gamma A_5A_6G_4G_5 + bck\omega G_6 + \omega A_5A_6G_2G_6 - A_5A_6G_1G_4G_6 - \gamma \omega A_5A_6G_7 + A_5A_6G_1G_3G_7$

Which becomes $bckG_3G_5 + A_5A_6G_2G_3G_5 + bck\omega G_6 + \omega A_5A_6G_2G_6 - A_5A_6[\gamma G_4G_5 + \gamma \omega G_7 + G_1G_4G_6 - G_1G_3G_7]$

Which is positive if

$$bckF_{3}G_{5} + A_{5}A_{6}G_{2}G_{3}G_{5} + bck\omega G_{6} + \omega A_{5}A_{6}G_{2}G_{6} > A_{5}A_{6}[\gamma G_{4}G_{5} + \gamma \omega G_{7} + G_{1}G_{4}G_{6} - G_{1}G_{3}G_{7}]$$
(2.32)

From stability theory [19], if the inequalities in equation 2.31 and equation 2.32 hold, then the system in equation 2.1 is asymptotically stable.

3 Numerical simulation and analysis

Through the use of numerical simulations, we examine the behaviour of transmission dynamics of Rotavirus as given in the formulated model. The parameter values, adapted from [7, 32], are used in simulating the graphs of the formulated model. These parameter values are varied and their impact on the model explored. In this section, Matlab software is used to illustrate the numerical simulations describing the theoretical results for the system in equation 2.1.

3.1 Model in equation 2.1 with no vaccination and $\tau = 0$

In this subsection, we will numerically simulate equation 2.1 with no vaccination and $\tau = 0$. The initial populations are given by S(0)=12, I(0)=5, T(0)=2, R(0)=1. The parameter values used are $\Lambda = 4$, b =0.3, $\mu = 0.1 \ \delta = 0.04$, k=0.4, a=0.8 and c=0.2. For Fig 1, $\beta = 0.001$. For Fig. 2, $\beta = 0.03$. For Fig. 3, $\beta = 0.6$.

The following graphs are obtained:





In Fig. 1, when $R_0 < 1$, $(R_0 = 0.02)$; the susceptible population grows boundedly because the secondary infections from one infected individual are very few. Hence the infected, treated and recovered populations tend to zero.

In Fig. 2, when the $R_0 \rightarrow 1$, $(R_0 = 1.07)$; the susceptible population reduces slightly then increases and stabilizes after some time. The infected, treated and recovered population reduces gradually and stabilizes. All the four classes co-exist because $R_0 \rightarrow 1$, meaning that the secondary infections from one primary infection are not many.

In Fig. 3, when the $R_0 > 1$ and big ($R_0 = 13.73$); the susceptible population reduces sharply because the number of secondary infections are many from one primary infection, it stabilizes with time. The infected population increases sharply, and decreases before stabilizing. The treated and recovered population behave in the same manner as the infected population. This shows that when $R_0 > 1$ and big meaning that the disease will persist and therefore it is necessary to have $R_0 < 1$ and $R_0 \rightarrow 1$.

3.2 Model in equation 2.1 with $\tau = 0$

In this subsection, we will numerically simulate the model in equation 2.1 with $\tau = 0$. The initial populations are given by S(0)=12, V(0)=4, I(0)=5, T(0)=2, R(0)=1. The parameter values used are $\rho = 0.3$, $\Lambda = 4$, b=0.3, $\omega = 0.1 \ \mu = 0.1 \ \delta = 0.04$, k=0.4, a=0.8, c=0.2, $\gamma = 0.3$ and $\varepsilon = 0.9$. For Fig. 4, $\beta = 0.001$. For Fig. 5, $\beta = 0.03$. For Fig. 6, $\beta = 0.6$. The following graphs are obtained:



In Fig. 4, when $R_0 < 1$, $(R_0 = 0.42)$, the susceptible population grows boundedly because the secondary infections from one infected individual are few. Due to this fact, the infected, treated and recovered individuals tend to zero. The vaccinated population depends on the value of ω i.e it is a fraction of the susceptible population. In Fig. 5, when $R_0 \rightarrow 1$, $(R_0 = 1.07)$; the susceptible population increases and then slightly decreases after some time. The vaccinated population also increases. These two populations are increasing because $R_0 \rightarrow 1$. The infected and treated slightly decreases and stabilizes. The recovered population also stabilizes with time. All the five compartments co-exist because $R_0 \rightarrow 1$, meaning that the secondary infections from one primary infection are not many.

In Fig. 6, when $R_0 > 1$ and big ($R_0 = 13.73$); the susceptible population decreases sharply because the number of secondary infections are many from one primary infection. However the susceptible population stabilizes with time. This in turn affects the vaccinated population which decreases sharply and stabilizes. The infected population increases before stabilizing which affects the treated and recovered population in the same manner. This shows that when $R_0 > 1$ and big, the infected population will grow and therefore we need to have $R_0 < 1$ or $R_0 \rightarrow 1$.

3.3 Model in equation 2.1

In this section, we will numerically simulate equation 2.1 with either a small delay ($\tau = 0.01$) ≈ 4 days or a large delay ($\tau = 0.1$) ≈ 37 days. The initial populations are given by S(0)=12, V(0)=4, I(0)=5, T(0)=2, R(0)=1. The parameter values used are $\rho = 0.3$, $\Lambda = 4$, b =0.3, $\omega = 0.1$ $\mu = 0.1$ $\delta = 0.04$, k=0.4, a=0.8, c=0.2, $\gamma = 0.3$ and $\varepsilon = 0.9$. For Figs. 7 and 8, $\beta = 0.001$. For Figs. 9 and 10, $\beta = 0.03$. For Figs. 11 and 12, $\beta = 0.6$. For Figs. 7, 9 and 11, $\tau = 0.01$ whereas for Figs. 8, 10 and 12, $\tau = 0.1$ The following graphs are obtained:



In Figs. 7 and 8 when $R_0 < 1$ ($R_0 = 0.42$); the susceptible population grows boundedly because the secondary infections from one infected individual are few. Due to this fact, the infected, treated and recovered individuals ted to extinction. The vaccinated population depends on ω i.e it is a fraction of the susceptible. The impact of delay is not seen because $R_0 < 1$ i.e secondary number of infections are few.

In Figs. 9 and 10 when $R_0 > 1$ ($R_0 = 1.07$); the susceptible population increases and it then slightly decreases after some time before stabilizing. The vaccinated population increases and stabilizes after some time. The two populations are increasing because $R_0 \rightarrow 1$. The infected and treated population slightly decreases and stabilizes. The recovered population also stabilizes with time. All the five classes co-exist because $R_0 \rightarrow 1$,



meaning that the secondary infections from one primary infection are not many. The impact of delay is also not felt because $R_0 \rightarrow 1$.

In Figs. 11 and 12 $R_0 > 1$ ($R_0 = 13.73$), when $\tau = 0.01$; the susceptible population decreases sharply because the number of secondary infections are many from one primary infection. However the susceptible population stabilizes with time. This in turn affects the vaccinated population which decreases sharply and stabilizes. The infected population increases before stabilizing. The treated and recovered population behave in the same way as the infected population. This shows that when $R_0 > 1$ and big, the infected population will grow and therefore we need to have $R_0 < 1$ or $R_0 \rightarrow 1$. When $\tau = 0.1$, the compartments behave in the same way, but it takes a longer time to stabilize showing that when τ is large the population will be greatly affected and therefore there is need to have $\tau = 0.1$ reduced for favourable environment in the system.

4 Conclusion

A model to determine Rotavirus infection incorporating time delay on the effectiveness of vaccination with treatment was formulated and shown to be positively invariant as well as bounded. The basic reproduction number R_0 corresponding to Rotavirus was determined. R_0 which plays the role in controlling the spread of the infection of the disease was determined by use next generation matrix. The existence and analysis of equilibrium points were established. The disease free equilibrium point was shown to be asymptotically stable, implying that the disease outbreak for life was not expected. By use of Routh-Hurwitz criterion, the endemic equilibrium point was shown to be locally asymptotically stable. The disease transmission levels could be kept quite low with minimal deaths and interferences at the peak times of re-occurrences if R_0 is maintained at $R_0 < 1$ or $R_0 \rightarrow 1$.

Numerical simulation showed that, when $R_0 < 1$ or $R_0 \rightarrow 1$, the susceptible population would not decrease drastically neither would the infected population rise drastically unlike when $R_0 > 1$. When R_0 is big, a bigger time delay would make the population to oscillate meaning that the population was not predictable.

5 Recommendation

Authorities in the public health, health practitioners and epidemiologists can use the formulated model to understand the spread and control of the infection of the Rotavirus. The health agencies can get better understanding on the role of delay on the effectiveness of vaccination with treatment associated to Rotavirus in order to respond to the associated infection. Recommendations for future studies; even though the results obtained were in improving the health status of Rotavirus infection, there still improvements that were related to the research that could be implemented since the research could serve as the baseline for further studies. For instance, different geographical regions can be considered, since each region is affected by different dynamics.

Disclaimer (Artificial Intelligence)

Authors hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

Competing Interests

Authors have declared that no competing interests exist.

References

- Miles MG, Lewis KDC, Kang G, Parashar UD, Steele AD. A systematic review of rotavirus strain diversity in India, Bangladesh, and Pakistan. Vaccine. 2012;30:A131 A139.
- [2] World Health Organization. Rotavirus vaccines: WHO position paper. Wkly Epidemiol Rec 2007;82(August 32):285–96.
- [3] Bernstein DI, Ward RL. Rotaviruses. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. 5th ed. Vol 2. Philadelphia, PA: Saunders. 2004;2110–2133.
- [4] Onyango L, Chuncheng W, Xiaoping X, George L. Modelling the effects of vaccination on rotavirus infection. Advances in difference Equations. 2015;381:1-12.
- [5] Viriyapong R, Koompawan G. The impact of hygiene care and maternal immunity on stability behaviour of rotavirus infection model for children under the age of five in Thailand. International Journal of Mathematical Modelling and Numerical Optimisation. 2018;8(4):378-392.
- [6] Gruber JF, Becker-Dreps S, Hudgens MG, Brookhart MA, Thomas JC, Jonsson Funk M. Timing of rotavirus vaccine doses and severe rotavirus gastroenteritis among vaccinated infants in low- and middle-income countries; 2018.
- [7] Adongo FA, Onyango LO, Bonyo J, Lawi GO, Elisha OA. A delayed vaccination model for rotavirus infection. European Journal of Pure and Applied Mathematics. 2020;13(4):840-851.
- [8] Chaturvedi O, Masupe S, Lungu E. Epidemic model formulation, analysis and simulation of Rotavirus Diarrhea for prevention. Asian Research Journal of Mathematics. 2017;1-14.
- [9] Darti I, Suryanto A, Ilmi NB. Dynamical behavior of a rotavirus transmission model with an environmental effect. In AIP Conference Proceedings. AIP Publishing LLC. 2020, September;2264(1):020001
- [10] Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, Gentsch JR. Rotavirus vaccines: Current prospects and future challenges. The Lancet. 2006;368(9532):323–332.
- [11] World Health Organization et al. (2018): Immunization, vaccine and biologicals, highlights 2017-2018.
- [12] Van Den Driesche P, Watmough J. Reproduction number and sub-threshold endemic equillibria for compartmental models of disease transmission. Mathematical Bio Sciences. 2002;180:29–48.
- [13] Ilmi NB, Darti I, Suryanto A. Dynamical Analysis of a Rotavirus Infection Model with Vaccination and Saturation Incidence Rate. In Journal of Physics: Conference Series. 2020, June;1562(1):012018. IOP Publishing.

- [14] James A, Platts-Mills, Caroline A, Jean G, Rosemary N, Thomas W, et al. Impact of rotavirus vaccine introduction and postintroduction etiology of diarrhea requiring hospital admission in haydom, tanzania, a rural african setting. Clinical Infectious Diseases. 2017;65(7):1144–1151.
- [15] Omondi OL, Achieng O., Mwende TA GO L. Modeling malaria and rotavirus co-infection. Neural, Parallel, and Scientific Computation. 2018;26(2):143-168.
- [16] Escolano S, Mueller JE, Tubert-Bitter P. Accounting for indirect protection in the benefit-risk ratio estimation of rotavirus vaccination in children under the age of 5 years, France, 2018. Eurosurveillance. 2020;25(33):1900538.
- [17] Parashar U, Johnson H, Steele A, Tate J. Health impact of rotavirus vaccination in developing countries: progress and way forward. Clinical infectious Diseases. 2016;62(2):91–95.
- [18] Pitzer VE, Atkins KE, de Blasio BF, Van Effelterre T, Atchison CJ, Harris JP, Lopman BA. Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models. PloS one. 2012;7(8):e42320.
- [19] Rotavirus vaccines WHO position paper / Vaccine. 2013;31:6170–6171.
- [20] Van Effelterre T, Soriano-Gabarro M, Debrus S, Newbern EC, Gray J. A mathematical model of the indirect effects of rotavirus vaccination. Epidemiology & Infection. 2010;138(6):884-897.
- [21] Shim E, Feng Z, Martcheva M, Castillo-Chavez C. An age-structured epidemic model of rotavirus with vaccination. Journal of Mathematical Biology. 2006;53(4):719-746.
- [22] Virginia E, Katherine E, Birgitte F, Thierry V, Christina J, John P, Ben A. Direct and indirect effects of rotavirus vaccination comparing predictions from transmission dynamic models. Research Article Massey University, New Zealand; 2012.
- [23] Wandera E, Mohammad S, Bundi M, Nyangao J, Galata A, Kathiiko C, et al. Impact of rotavirus vaccination on rotavirus hospitalisation rates among a resource-limited rural population in Mbita, Western Kenya. Tropical Medicine and International Health. 2018;23(4):425–432.
- [24] World Health Organization. Rotavirus vaccines: WHO position paper—January 2013. Weekly Epidemiological Record Relevé épidémiologique hebdomadaire. 2013;88(5):49-64.
- [25] Pindyck T, Tate JE, Bonkoungou IJO, Armah G, Mujuru HA, Rugambwa C, Parashar U. Timeliness of rotavirus vaccination at sentinel sites in four early-adopter African countries. Vaccine. 2019;37(40):6002–6007.
- [26] Choudhary T, Reddy S, Apte A, Sinha B, Roy S, Nayana P, Sindhu K, Patil R, Upadhyay R, Chowdhury R. Delayed vaccination and its predictors among children under 2 years in India: Insights from the national family health survey-4; 2019.
- [27] Namawejje H, Livingstone S, Luboobi, Dmitry K, Eric W. Mathematical Model for the Effects of Treatment and Vaccination Controls on the Dynamics of Rotavirus Disease with Reference to Uganda, Reseach Article Makerere University, Kampala; 2014.
- [28] Khan Q, David G. Hopf bifurcation in epidemic models with a time delay in vaccination. Journal of Mathematics Applied in Medicine and Biology. 1997;16:113-142.
- [29] Kuang Y. Delay differential equations. University of California Press. 2012;163-166.
- [30] Rihan FA, Tunc C, Saker SH, Lakshmanan S, Rakkiyappan R. Applications of delay differential equations in biological systems. Department of Mathematical Sciences, College of Science, UAE University; 2018.

- [31] Olaniyi S, Obabiyi OS. Qualitative Analysis of Malaria Dynamics with non-linear Incidence Function. Applied Mathematical Sciences. 2014;8(78):3889–3904.
- [32] Shampine LF, Thompson S, Kierzenka J. Solving delay differential equations with dde23; 2000. Available:http://www.runet.edu/ thompson/webddes/tutorial.pdf.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here (Please copy paste the total link in your browser address bar)

https://www.sdiarticle5.com/review-history/120065